{"pmid":32243267,"title":"Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure.","text":["Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure.","ASAIO J","Bartlett, Robert H","Ogino, Mark T","Brodie, Daniel","McMullan, David M","Lorusso, Roberto","MacLaren, Graeme","Stead, Christine M","Rycus, Peter","Fraser, John F","Belohlavek, Jan","Salazar, Leonardo","Mehta, Yatin","Raman, Lakshmi","Paden, Matthew L","32243267"],"journal":"ASAIO J","authors":["Bartlett, Robert H","Ogino, Mark T","Brodie, Daniel","McMullan, David M","Lorusso, Roberto","MacLaren, Graeme","Stead, Christine M","Rycus, Peter","Fraser, John F","Belohlavek, Jan","Salazar, Leonardo","Mehta, Yatin","Raman, Lakshmi","Paden, Matthew L"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243267","week":"202014|Mar 30 - Apr 05","doi":"10.1097/MAT.0000000000001173","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663079112907948032,"score":7.6048946,"similar":[{"pmid":32223988,"title":"ECMO for ARDS due to COVID-19.","text":["ECMO for ARDS due to COVID-19.","Heart Lung","Namendys-Silva, Silvio A","32223988"],"journal":"Heart Lung","authors":["Namendys-Silva, Silvio A"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32223988","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.hrtlng.2020.03.012","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662819280276684801,"score":53.730865},{"pmid":32178774,"title":"COVID-19, ECMO, and lymphopenia: a word of caution.","text":["COVID-19, ECMO, and lymphopenia: a word of caution.","Lancet Respir Med","Henry, Brandon Michael","32178774"],"journal":"Lancet Respir Med","authors":["Henry, Brandon Michael"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178774","week":"202012|Mar 16 - Mar 22","doi":"10.1016/S2213-2600(20)30119-3","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543590326272,"score":51.220207},{"pmid":32203711,"title":"Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","text":["Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality.","Lancet Respir Med","Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran","32203711"],"abstract":["WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality."],"journal":"Lancet Respir Med","authors":["Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203711","week":"202013|Mar 23 - Mar 29","doi":"10.1016/S2213-2600(20)30121-1","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1662334543341813760,"score":47.96093},{"pmid":32048501,"title":"[Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy].","text":["[Respiratory support for severe 2019-nCoV pneumonia suffering from acute respiratory failure: time and strategy].","Respiratory support is a very important technique for saving severe 2019-nCoV pneumonia patients who suffering respiratory failure, which can improve oxygenation, reduce mortality. Therefore, how to reasonable using respiratory support technique is the key point that relating success or failure. In this paper, the authors introduce their experience on treating severe 2019-nCoV pneumonia, it is hopeful for current fighting against 2019-nCoV in China.","Zhonghua Jie He He Hu Xi Za Zhi","Yuan, X","Mu, J S","Mo, G X","Hu, X S","Yan, P","Xie, L X","32048501"],"abstract":["Respiratory support is a very important technique for saving severe 2019-nCoV pneumonia patients who suffering respiratory failure, which can improve oxygenation, reduce mortality. Therefore, how to reasonable using respiratory support technique is the key point that relating success or failure. In this paper, the authors introduce their experience on treating severe 2019-nCoV pneumonia, it is hopeful for current fighting against 2019-nCoV in China."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Yuan, X","Mu, J S","Mo, G X","Hu, X S","Yan, P","Xie, L X"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32048501","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0010","keywords":["2019-nCoV","Oxygenation","Respiratory failure","Respiratory support"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1662334544522510336,"score":42.16867},{"pmid":32189428,"title":"Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","text":["Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells.","FEBS J","Olds, James L","Kabbani, Nadine","32189428"],"abstract":["The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells."],"journal":"FEBS J","authors":["Olds, James L","Kabbani, Nadine"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32189428","week":"202012|Mar 16 - Mar 22","doi":"10.1111/febs.15303","keywords":["addiction","infectious Disease","pandemic","public Health","tobacco"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663095625913204737,"score":40.82104}]}